The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.

This study assessed nutrient intake in adults using GLP-1 receptor agonists (GLP-1RAs) and found widespread deficiencies in ...

Share on Pinterest A new study shows GLP-1 drugs liraglutide ... Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections.

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

The problem was resolved Thursday, when lawmakers sent a $240 million supplemental budget to Governor Maura Healey, which she ...

That's according to the study funded by ... taking semaglutide. The GLP-1 drugs have become increasingly popular, with at least 1 in 8 U.S. adults reporting their use, according to a 2024 survey ...

Less than 3% of all people in the U.S. who are eligible for injectable weight loss drugs receive a prescription for it, according to a new study from ... like peptide-1 (GLP-1) agonists are ...

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new data from a late-stage study of the GLP-1 receptor agonist ... protection ...